Innovus Pharma Announces the Launch of RecalMax™ A Clinically Proven Product for Brain Health in the U.S.
Product Targets a $3 Billion Market
SAN DIEGO–(BUSINESS WIRE)–Innovus
Pharmaceuticals, Inc. (“Innovus Pharma”) (OTCQB Venture Market:
INNV), an emerging commercial stage pharmaceutical company that delivers
safe, innovative and effective over-the-counter medicine
and consumer care products to improve men and women’s health and
respiratory diseases, today announced the launch of its brain health
supplement, RecalMax™,
in the U.S. An estimated 12 million people suffer from neurodegenerative
diseases such as Alzheimer’s, for which the use of RecalMax™ may help,
in the U.S., Europe, and Japan. That represents an estimated market of more
than $3 billion per year.
The product will be available through www.recalmax.com
and in over 1,000 newspapers and prints in the U.S.
As previously
announced, RecalMax™ was tested in the U.S. in a four month human
survey use clinical trial in 72 patients with low memory and learning.
The patients were given one capsule twice a day for 16 weeks. Their
performance on tests and their satisfaction levels were assessed at the
beginning of the trial, at the midpoint, and at the end.
The results of RecalMax™ use included:
1. 115% increase in the recall of words and names
2. 49.5% increase
in maintaining thoughts when distracted
3. 35% increase in
processing speed
The data also showed that RecalMax™ is very well tolerated with no
serious adverse events. The only minor events reported were episodes of
dry mouth, which were resolved by drinking 62oz of water daily, and
sleep disturbances if taken in the late afternoon.
RecalMax™ is a proprietary oral low dose formulation of two important
amino acids, L-Citrulline and L-Arginine, along with a natural
absorption enhancer called Bioperine®. The body converts L-Arginine to a
substance called nitric oxide, which then sends a signal for blood
vessels to relax. The result is increased
blood flow to the brain, which is expected to improve cognitive
functioning.
As the population ages, the market for treatment approaches for all
neurodegenerative diseases is expected to grow rapidly, possibly
climbing past $20 billion.
“We believe RecalMax™ could generate close to $5 million a year, adding
to the revenues already being generated by the success of our Vesele®
dietary supplement,” said Innovus CEO Dr.
Bassam Damaj. “We are marketing RecalMax™ under our Beyond Human
platform, which targets over 1,000 newspapers in the U.S. and more than
1.5 million online subscribers to our websites.”
About RecalMax™
RecalMax™ is a proprietary, novel oral dietary supplement to maximize
nitric oxide’s beneficial effects on brain health. RecalMax™ contains a
patented formulation of low dose L-Arginine and L-Citrulline, in
combination with the natural absorption enhancer Bioperine®. For more
information visit www.recalmax.com.
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC
and consumer products for men’s and women’s health and vitality. The
Company generates revenues from its lead
products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent,
(c) Zestra® for female arousal and (d) EjectDelay® for premature
ejaculation and has an additional five marketed products in this space,
including (e) Sensum+® for the indication of reduced penile sensitivity,
(for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for
promoting sexual and cognitive health, (i) Androferti® (in the U.S. and
Canada) to support overall male reproductive health and sperm quality,
(j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually
FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the
U.S. FDA.
For more information, go to www.innovuspharma.com,
www.zestra.com;
www.ejectdelay.com;
www.myvesele.com;
www.sensumplus.com;
www.myandroferti.com;
www.beyondhumantestosterone.com;
www.getbeyondhuman.com;
www.trybeyondhuman.com;
www.recalmax.com.
Innovus Pharma’s Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, projected revenues, projected online subscribers, estimated market
for its products, and statements about achieving its other development,
growth, commercialization, financial and staffing objectives. Readers
are cautioned not to place undue reliance on these forward-looking
statements as actual results could differ materially from the
forward-looking statements contained herein. Readers are urged to read
the risk factors set forth in the Company’s most recent annual report on
Form 10-K, subsequent quarterly reports filed on Form 10-Q and other
filings made with the SEC. Copies of these reports are available from
the SEC’s website or without charge from the Company.
Contacts
Brokers and Analysts
Chesapeake Group
Kevin Holmes,
410-825-3930
info@chesapeakegp.com
